菅原正弘 院長 最近の主要な共著論文（JAMA 等、欧米主要学会誌に掲載されています）
１）Low-dose aspirin for primary prevention of cardiovascular events in Japanesepatients 60 years or older with atherosclerotic risk factors: arandomized clinical trial.
Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, Sugawara M,
Ando K, Murata M, Yokoyama K, Ishizuka N.
JAMA. 2014 Dec 17;312(23):2510-20.
２）Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy.
Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N,Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, Sugawara
M, Ohya Y, Kimura K, Saito Y, Ogawa H.
Eur Heart J. 2019 Jun 7;40(22):1778-1786.
３）Sodium-glucose cotransporter 2 inhibitor-induced changes in body compositionand simultaneous changes in metabolic profile: 52-week prospective LIGHT(Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2
Diabetes Mellitus) Study.
Sasaki T, Sugawara M, Fukuda M.」
J Diabetes Investig. 2019 Jan;10(1):108-117.
４）Rationale, design, and baseline characteristics of a study to evaluate the effect offebuxostat in preventing cerebral, cardiovascular, and renal events in patients withhyperuricemia.
Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai
N, Tokutake E, Uchiyama K, Sugawara M, Kakuda H, Wakasa Y, Mori H, Hisatome I,Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiorenovascular
Events Prevention Study (FREED) investigators.
J Cardiol. 2017 Jan;69(1):169-175.

５）Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.
Ohmura H, Mita T, Taneda Y, Sugawara M, Funayama H, Matsuoka J, Watada H,Daida H; SPIRITS-J Study Investigators.

J Clin Med Res. 2015 Apr;7(4):211-9.

６）Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors:
Japanese Primary Prevention Project.
Uchiyama S, Ishizuka N, Shimada K, Teramoto T, Yamazaki T, Oikawa S, Sugawara
M, Ando K, Murata M, Yokoyama K, Minematsu K, Matsumoto M, Ikeda Y; JPPP
Study Group.
Stroke. 2016 Jun;47(6):1605-11.
７）Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese.
Yokoyama K, Ishizuka N, Uemura N, Mizokami Y, Hiraishi H, Murata M, Uchiyama S,Teramoto T, Shimada K, Yamazaki T, Oikawa S, Sugawara M, Ando K, Ikeda Y; JPPP
study group.
Res Pract Thromb Haemost. 2018 Apr 15;2(2):274-281.
８）Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus:
A focus on hypoglycemia.
Fukuda M, Doi K, Sugawara M, Mochizuki K.
J Diabetes Investig. 2019 Mar;10(2):383-391.
９）Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With
Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study.
Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J,Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M,Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S,Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y,Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K,Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.
Diabetes Care. 2018 Jun;41(6):1275-1284.
１０）Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly
Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a
Randomized Clinical Trial (JPPP-70).

Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, Uchiyama S,Ando K, Ishizuka N, Murata M, Yokoyama K, Uemura Y, Ikeda Y; Japanese Primary
Prevention Project (JPPP) Study Group.
Am J Cardiovasc Drugs. 2019Jun;19(3):299-311.
１１）Influence of blood pressure on the effects of low-dose asprin in elderly patientswith multiple atherosclerotic risks.
Ando K, Shimada K, Yamazaki T, Uchiyama S, Uemura Y, Ishizuka N, Teramoto T,
Oikawa S, Sugawara M, Murata M, Yokoyama K, Ikeda Y; Japanese Primary
Prevention Project (JPPP) Study Group.
J Hypertens. 2019 Jun;37(6):1301-1307.
１２）Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra
cardiovascular protection in patients at high risk: Exploratory analysis of theStandard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia
and Diabetic Retinopathy study.
Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J,
Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M,
Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S,Saito Y, Seino Y, Shigeeda T, Shindo S, Sugawara M, Sugiyama S, Terauchi Y,
Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K,Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.
Diabetes Obes Metab. 2019 Apr;21(4):791-800.
１３）Differences between rosuvastatin and atorvastatin in lipid-lowering action andeffect on glucose metabolism in Japanese hypercholesterolemic patients withconcurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with
type 2 diabetes patients (LISTEN) study –.
Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, Sugawara M, Masuda I, MoriH, Waki M, Yoshiyama M, Watada H.
Circ J. 2014;78(10):2512-5.
１４）Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy anduric acid metabolism in hypertensive patients with chronic kidney disease (JCIRCLE study).

Uchida S, Takahashi M, Sugawara M, Saito T, Nakai K, Fujita M, Mochizuki K, Shin I,Morita T, Hikita T, Itakura H, Takahashi Y, Mizuno S, Ohno Y, Ito K, Ito T, Soma M.JClin Hypertens (Greenwich). 2014 Oct;16(10):746-53
１５）Optimal Combination of Effective ANtihypertensives (OCEAN) study: aprospective, randomized, open-label, blinded endpoint trial--rationale, design andresults of a pilot study in Japan.
Kageyama S, Ueda S, Mochizuki K, Miyakawa M, Sugawara M, Nakayama M, Ohashi
Y, Saito I, Saruta T; OCEAN Study Group.
Hypertens Res. 2012 Feb;35(2):221-7.
１６）[Influence of physicians' subspecialty and training history on CKD managementand medical cooperation: from the results of a nationwide questionnaire survey forprimary care physicians].
Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M, Naka Y, Saruta
T.Nihon Jinzo Gakkai Shi. 2013;55(8):1401-11.
１７）[Current status of and regional differences in CKD management and medicalcooperation in Japan: from the results of a nationwide questionnaire survey forprimary care physicians].
Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, Sugawara M, Naka Y, Saruta
T.Nihon Jinzo Gakkai Shi. 2013;55(8):1391-400.
１８）The relationship between initial clinical manifestation and long-term prognosis ofpatients with systemic lupus erythematosus.
Tokano Y, Morimoto S, Amano H, Kawanishi T, Yano T, Tomyo M, Sugawara M,
Kobayashi S, Tsuda H, Takasaki Y, Hashimoto H.
Mod Rheumatol. 2005;15(4):275-82.